Efrat Harel
YOU?
Author Swipe
View article: Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer
Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer Open
A promising molecular target for aggressive cancers is the urokinase receptor (uPAR). A fully human, recombinant antibody that binds uPAR to form a stable complex that blocks uPA-uPAR interactions (2G10) and is internalized primarily throu…
View article: Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes
Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes Open
Background. The role of the soluble urokinase plasminogen activator receptor (suPAR) in focal segmental glomerulosclerosis (FSGS) as the circulating factor or as a predictor of recurrence after transplantation remains controversial. Previo…
View article: P43 THE ROLE OF B7.1 AND suPAR IN PODOCYTE INJURY AND FOCAL SEGMENTAL GLOMERULOSCLEROSIS
P43 THE ROLE OF B7.1 AND suPAR IN PODOCYTE INJURY AND FOCAL SEGMENTAL GLOMERULOSCLEROSIS Open
View article: SP146THE ROLE OF B7.1 AND suPAR IN PODOCYTE INJURY AND FOCAL SEGMENTAL GLOMERULOSCLEROSIS
SP146THE ROLE OF B7.1 AND suPAR IN PODOCYTE INJURY AND FOCAL SEGMENTAL GLOMERULOSCLEROSIS Open
View article: The Anti-Inflammatory Activity of a Novel Fused-Cyclopentenone Phosphonate and Its Potential in the Local Treatment of Experimental Colitis
The Anti-Inflammatory Activity of a Novel Fused-Cyclopentenone Phosphonate and Its Potential in the Local Treatment of Experimental Colitis Open
A novel fused-cyclopentenone phosphonate compound, namely, diethyl 3-nonyl-5-oxo-3,5,6,6a-tetrahydro-1 H -cyclopenta[ c ]furan-4-ylphosphonate (P-5), was prepared and tested in vitro (LPS-activated macrophages) for its cytotoxicity and ant…